February 25, 2014

Press Release No. 1

News about Pfizer Limited

The media had reports that "Pfizer Stock Gains Over 20% on Stake Recast Plans".

The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company.

Pfizer Limited has vide its letter inter-alia stated,"The news article is speculative and was not authorized by, or attributable to any statements made by or on behalf of, Pfizer Limited. For instance, the article mentions unsubstantiated market rumours of a possible delisting of Pfizer Limited. Pfizer Limited is not aware of any discussions or proposals by its promoters to delist the company's shares from Indian markets. As regards the transfer of shares of Pfizer Limited, such transaction is being undertaken directly between shareholders of Pfizer Limited and to which, Pfizer Limited was not a transacting party. Pfizer Limited understands that fillings have been made by the acquiring entity i.e. Pfizer East India B.V., Netherlands, under applicable provisions of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. We understand that such transfers are being undertaken as part of the global internal corporate restructuring plan of the Pfizer Group, as reported by us previously. We do not believe that the present transfers have bearing on the stock price of Pfizer Limited, given especially that ultimate control of Pfizer Limited remains unchanged."

Press Release No. 2

Market-wide Position Limit in AUROPHARMA

The derivative contracts in the underlying AUROPHARMA have crossed 95% of the market-wide position limit on Feb 25, 2014. It is hereby informed that all clients/ members shall trade in derivative contracts of AUROPHARMA by offsetting their existing positions till the open interest comes down to 80% of the market wide position limit.